Coronavirus: Sanofi offers 100 million doses of hydroxychloroquine in COVID-19 fight | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
January 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, JANUARY 28, 2023
Sanofi offers 100 million doses of hydroxychloroquine in COVID-19 fight

Coronavirus chronicle

BSS/AFP
11 April, 2020, 09:30 am
Last modified: 11 April, 2020, 12:09 pm

Related News

  • India launches world’s 1st intranasal Covid vaccine
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • China says Covid deaths down by nearly 80 percent
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • US proposes once-a-year Covid shots for most Americans

Sanofi offers 100 million doses of hydroxychloroquine in COVID-19 fight

Both hydroxychloroquine, which Sanofi sells under the brand name Plaquenil, and the related compound chloroquine, an anti-malarial drug, are being studied worldwide as potential weapons in the coronavirus fight

BSS/AFP
11 April, 2020, 09:30 am
Last modified: 11 April, 2020, 12:09 pm
Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, US March 31, 2020/ Reuters
Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, US March 31, 2020/ Reuters

French pharmaceutical giant Sanofi said Friday it would offer 100 million doses of hydroxychloroquine, a treatment for rheumatoid arthritis and lupus, to governments worldwide if studies show it can safely to be used to treat COVID-19 patients.

Both hydroxychloroquine, which Sanofi sells under the brand name Plaquenil, and the related compound chloroquine, an anti-malarial drug, are being studied worldwide as potential weapons in the coronavirus fight.

But proposals to put them to use immediately for more patients have proven highly controversial, with many experts warning there is not yet enough evidence of their safety or effectiveness against COVID-19.

A French doctor in particular, Didier Raoult, has raised hopes by treating patients with a combination of hydroxychloroquine (HQC) and the antibiotic azithromycin, an initiative that many health officials refuse to endorse in the absence of more rigorous studies.

On Thursday, French President Emmanuel Macron met Raoult and his team in Marseille to discuss their latest findings, though the president did not comment publicly on the meeting afterward.

Sanofi acknowledged that "interpretations of the available preliminary data on hydroxychloroquine in the management of COVID-19 differ widely.

"While hydroxychloroquine is generating a lot of hope for patients around the world, it should be remembered that there are no results from ongoing studies, and the results may be positive or negative."

But chief executive Paul Hudson said in a statement, "If the trials prove positive, we hope our donation will play a critical role for patients."

Other companies have also pledged to offer the drugs, with Switzerland's Novartis proposing 130 million doses of chloroquine, and Israeli generic producer Teva promising 10 million doses of HQC for US hospitals.

Sanofi is also working on a potential vaccine for the new coronavirus, which has killed more than 94,000 people worldwide since cases were first reported in China last December.

Top News

Sanofi / hydroxychloroquine / Coronavirus / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • How will Bangladesh pay for massive upcoming power projects this year?
    How will Bangladesh pay for massive upcoming power projects this year?
  • Israeli forces work next to a covered body at the scene of a shooting attack in Neve Yaacov which lies on occupied land that Israel annexed to Jerusalem after the 1967 Middle East war January 27, 2023. REUTERS/Ammar Awad
    Seven dead in synagogue attack outside Jerusalem
  • Now is the time to focus on FDI composition
    Now is the time to focus on FDI composition

MOST VIEWED

  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC
  • People embrace at the international arrivals gate at Beijing Capital International Airport after China lifted the coronavirus disease (COVID-19) quarantine requirement for inbound travellers in Beijing, China January 8, 2023. REUTERS/Thomas Peter
    China says peak Covid infections exceeded 7 million daily, deaths more than 4,000 daily
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    US proposes once-a-year Covid shots for most Americans

Related News

  • India launches world’s 1st intranasal Covid vaccine
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • China says Covid deaths down by nearly 80 percent
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • US proposes once-a-year Covid shots for most Americans

Features

Now is the time to focus on FDI composition

Now is the time to focus on FDI composition

Now | Panorama
Sketch:TBS

Why we need consumer education for consumer wellbeing

20h | Thoughts
Dr Ahsan H Mansur, Executive Director, Policy Research Institute. Illustration: TBS

Twin shocks call for stronger domestic policy response

21h | Thoughts
December-er shohor, taxi taken for airport and the Park Street bathed in lights. Photo: Jannatul Naym Pieal

Exploring Kolkata on foot, empowered by Google Maps

21h | Explorer

More Videos from TBS

Kajol’s road paintings bring change in Gafargaon

Kajol’s road paintings bring change in Gafargaon

1d | TBS Stories
Carew & Company witnessed a remarkable growth

Carew & Company witnessed a remarkable growth

1d | TBS Stories
Gavi may have to leave Camp Nou

Gavi may have to leave Camp Nou

10h | TBS SPORTS
After all the controversies, how is Shah Rukh Khan's ‘Pathaan’?

After all the controversies, how is Shah Rukh Khan's ‘Pathaan’?

12h | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Four top bankers arrested in DSA case filed by S Alam group 
Bangladesh

Four top bankers arrested in DSA case filed by S Alam group 

3
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]